The “Flolan Rash” | Great Cases from the JDD
INTRODUCTION
Epoprostenol (Flolan) is a last-resort intravenous (IV) medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, though lacking in dermatologic literature.1 We report an extensive near erythrodermic appearing asymptomatic eruption following long-term use of epoprostenol. This characteristic and …
INTRODUCTION
Epoprostenol (Flolan) is a last-resort intravenous (IV) medication for the treatment of severe pulmonary arterial hypertension (PAH). Cutaneous adverse events of Flolan are well-known by pulmonologists, though lacking in dermatologic literature.1 We report an extensive near erythrodermic appearing asymptomatic eruption following long-term use of epoprostenol. This characteristic and … Continue reading "The “Flolan Rash” | Great Cases from the JDD"
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … 
The November issue of the Journal of Drugs in Dermatology (JDD) focuses on lasers, lights sources, and devices featuring original articles and case reports exploring topics such as combination of platelet rich plasma and 1550 nm fractional laser for androgenetic alopecia, safety of combination laser procedures in single clinic visit, efficacy of a fractionated 1540 nm erbium glass laser in the tre … 
Verrucous psoriasis (VP) is a rare histologic variant of psoriasis. To date, fewer than 40 cases have been reported, with pediatric cases representing an exceedingly small fraction. Treatment options are limited, and the disease is often refractory to conventional methods. Herein, JDD authors Samantha Sherkin OMS-IV, Christian Summa OMS-IV, David Crasto DO, Zackary Whitney DO, Lazlo Karai MD PhD,� … 
JDD authors Hannah Polster MD, Karen Kagha MD, and Janiene Luke MD report a case of platelet rich plasma for the treatment of scarring alopecia due to discoid lupus erythematosus.
Platelet-rich plasma (PRP) is an autologous concentration of plasma from a patient's blood containing platelets up to 7 times higher than normal plasma.1 Originally indicated to improve connective tissue regeneratio … 